Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Eli Lilly Q3 2026 Earnings Analysis cover art

Eli Lilly Q3 2026 Earnings Analysis

Eli Lilly Q3 2026 Earnings Analysis

Listen for free

View show details
About this listen
More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Eli Lilly's Q3 2026 results — and folks, this is a big one.

**JORDAN:** Huge one. Stock popped over 6.5% on the news.

**ALEX:** It really did. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Important stuff. Okay, Alex, let's talk numbers because they're staggering.

**ALEX:** Revenue grew 39% year-over-year — that's nearly $7 billion in additional revenue in a single quarter. Non-GAAP EPS came in at $7.48, and gross margin actually expanded to 84.4%.

**JORDAN:** And the guidance raise is what really got everyone's attention. Full-year revenue guidance moved up to $91-92 billion, and EPS guidance jumped to $35-36 — that's roughly a $4 per share increase at the midpoint from where they were tracking before.

**ALEX:** Which is wild because this isn't the first raise this year. CFO Lucas Montarce basically said they've now raised full-year revenue guidance by about $10 billion since the start of 2026.

**JORDAN:** And when analysts pushed on that — like, "are you guys just being too conservative?" — CEO David Ricks had a great answer. He basically said, look, we're in the middle of the largest category expansion in pharma history. There's real uncertainty here, and he'd rather beat estimates than miss them. Two big unknowns this year were the Medicare bridge program uptake and how deep international out-of-pocket demand would go — and both surprised to the upside.

**ALEX:** Let's talk about that Medicare bridge program because it's honestly the story of the quarter. This opened up obesity medicine access to about 20 million seniors starting July 1st, and in just one quarter, over half a million people already filled a prescription.

**JORDAN:** And Lilly is absolutely dominating that channel — 7 out of 10 new bridge patients are starting on a Lilly medicine. There was even a USC Schaeffer Center study cited saying this program could save Medicare over $20 billion cumulatively over ten years. That's a pretty powerful argument for why this program might get extended or made permanent.

**ALEX:** Right, and that was actually a direct question in the Q&A — will this bridge program survive past 2026? Ricks sounded genuinely optimistic, citing strong uptake, appropriate use based on BMI and comorbidities, and that cost-effectiveness data. He thinks it could get folded into the permanent Part D benefit going forward.

**JORDAN:** Let's not overlook the core business though — Mounjaro and Zepbound combined for over $16 billion in the quarter alone, contributing $6 billion of year-over-year growth. China was a standout too — Mounjaro became the first medicine there ever to cross $1 billion in its first full year, with 62% constant currency growth.

**ALEX:** And it's not just incretins anymore. Management specifically called out that oncology, immunology, and neuroscience revenue combined actually doubled year-over-year. Jaypirca up 59%, Ebglyss up 59%, and Kisunla — their Alzheimer's drug — up a staggering 175%.

**JORDAN:** That diversification story matters. David Ricks made a point of saying three-fourths of their clinical pipeline is actually outside of obesity. They don't want to be a one-trick pony, even though the trick is working extremely well right now.

**ALEX:** Speaking of the pipeline, there was some really juicy data this quarter. Retatrutide — their triple agonist — went head-to-head with semaglutide in type 2 diabetics and basically more than doubled the weight loss, 20-21% versus 9.4%.

**JORDAN:** And then there

This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet